Get the Stockscreener App
442.36
4.02%
17.08
After Hours:
440.88
-1.48
-0.33%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $442.36, with a volume of 2.54M.
It is up +4.02% in the last 24 hours and up +20.77% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$425.28
Open:
$430.24
24h Volume:
2.54M
Relative Volume:
0.96
Market Cap:
$239.32B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
30.76
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+6.29%
1M Performance:
+20.77%
6M Performance:
+17.81%
1Y Performance:
+49.67%
1-Day Range:
$429.38
$443.20
1-Week Range:
$410.40
$443.20
52-Week Range:
$269.77
$443.20
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
442.36 | 230.08B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,280.34 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.41 | 653.35B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.97 | 457.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
152.20 | 333.49B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
160.31 | 293.76B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Inc (AMGN) Shares Surge 4.0% -- What GF Score of 79 Tells Investors - GuruFocus
Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen? - 247wallst.com
Amgen Inc Stock (AMGN) Moved Up by 3.19% on Aug 19: What Investors Need To Know - TradingKey
Amgen Stock Surges 3.5% as Healthcare Hits Record High - Yahoo Finance
Amgen cans its TScan partnership; Amylyx reveals $350M offering - Endpoints News
Argus Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? - The Motley Fool
Amgen Inc. $AMGN Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd. - MarketBeat
Trust Co. of Vermont Purchases New Position in Amgen Inc. $AMGN - MarketBeat
ETFs Investing in Amgen Inc. Stocks - TradingView
Pharma in hackers' crosshairs as Amgen breach moves to courts - The Pharma Letter
Commerzbank Aktiengesellschaft FI Acquires 14,693 Shares of Amgen Inc. $AMGN - MarketBeat
AMG National Trust Bank Has $3.57 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock extends 2026 rally as Q2 earnings beat and guidance lifted - Ad-hoc-news.de
ANTITRUST NEWS—4th Cir.: FTC: Amgen’s Enbrel patent-application deal is subject to antitrust scrutiny - vitallaw.com
TScan TherapeuticsAmgen To Terminate Research Collaboration And License Agreement With TScan TherapeuticsSEC Filing - TradingView
TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration - Stock Titan
Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains - marketwatch.com
Can Amgen (NASDAQ:AMGN) Extend Its Record-High Momentum? - Kalkine Media
Amgen (NASDAQ:AMGN) Results Put Growth Back In Focus - Kalkine Media
The Bull Case For Amgen (AMGN) Could Change Following Raised 2026 Earnings Guidance And Q2 BeatLearn Why - simplywall.st
Cantor Fitzgerald raises Amgen stock price target on core portfolio strength - Investing.com India
Amgen (NASDAQ:AMGN) Reaches New 1-Year High on Analyst Upgrade - MarketBeat
Amgen stock hits all-time high at 422.49 USD - Investing.com
Amgen stock hits all-time high at 422.49 USD By Investing.com - Investing.com India
Resilient Amgen stock trades above $419 as earnings beat and 2026 guidance support momentum - AD HOC NEWS
Amgen (NASDAQ:AMGN) Given New $352.00 Price Target at Mizuho - MarketBeat
Cantor Fitzgerald Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
AMGN Maintains by Cantor Fitzgerald -- Price Target Raised to $4 - GuruFocus
Wilkinson Global Asset Management LLC Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Russell Investments Group Ltd. Sells 37,910 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Kinsale Capital Group Inc. - MarketBeat
Mitsubishi UFJ Trust & Banking Corp Purchases 5,903 Shares of Amgen Inc. $AMGN - MarketBeat
Kelleher Financial Advisors Buys 2,580 Shares of Amgen Inc. $AMGN - MarketBeat
Jessica Merrill: Mid-Cap Biopharma's $1B-Plus Deal Surge Could Spawn the Next Amgen - finance.biggo.com
Global Retirement Partners LLC Takes $8.88 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds above $415 as Q2 2026 growth and guidance support valuation - AD HOC NEWS
Amgen Inc. stock outperforms competitors on strong trading day - marketwatch.com
Mizuho Securities Adjusts Amgen Price Target to $352 From $303 - marketscreener.com
Amgen stock holds firm after Q2 sales raised the bar - ad-hoc-news.de
AMGN DCF Analysis: Intrinsic Value $296 vs Price $415 - GuruFocus
KBC Group NV Acquires 130,497 Shares of Amgen Inc. $AMGN - MarketBeat
HighTower Advisors LLC Has $295.58 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Lessened by Fifth Third Bancorp - MarketBeat
Amgen Inc. $AMGN Shares Bought by Bridgewater Advisors Inc. - MarketBeat
111 Capital Has $1.40 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as analyst lifts price target on obesity drug focus - AD HOC NEWS
Should Income Investors Look At Amgen Inc. (NASDAQ:AMGN) Before Its Ex-Dividend? - simplywall.st
Amgen Inc. $AMGN Shares Sold by Strive Financial Group LLC - MarketBeat
Principal Financial Group Inc. Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co. - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):